Related Experiment Video
Updated: Apr 30, 2026
04:11
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
5.5K
Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications
Teresa Pollicino1, Irene Cacciola2, Francesca Saffioti2
1Division of Clinical and Molecular Hepatology, University Hospital of Messina, Via Consolare Valeria, 1, 98124 Messina, Italy; Department of Pediatric, Gynecologic, Microbiological and Biomedical Sciences, University Hospital of Messina, Via Consolare Valeria, 1, 98124 Messina, Italy.
Journal of Hepatology
|May 8, 2014
Summary
Hepatitis B virus (HBV) preS/S variants can cause liver disease and cancer. These mutations lead to protein buildup, DNA damage, and immune evasion, impacting treatment outcomes.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Hepatitis B virus (HBV) preS/S variants frequently emerge spontaneously or due to treatment.
- These mutations can lead to significant pathobiological and clinical consequences.
Purpose of the Study:
- To investigate the implications of preS/S variants in HBV infection.
- To understand the mechanisms by which these variants cause disease progression.
Main Methods:
- Review of experimental data and human studies on preS/S mutations.
- Analysis of protein synthesis, endoplasmic reticulum (ER) retention, and ER stress induction.
- Assessment of oxidative DNA damage, genomic instability, and clinical outcomes.
Main Results:
- Specific preS/S mutations cause surface protein imbalance and ER retention in hepatocytes.
- Mutated protein accumulation induces ER stress, oxidative DNA damage, and genomic instability.
- Antigenically altered variants can infect immune-prophylaxed individuals, leading to occult HBV infection, fulminant hepatitis, fibrosing cholestatic hepatitis, cirrhosis, and hepatocellular carcinoma.
Conclusions:
- PreS/S variants are key drivers of HBV pathogenesis and disease progression.
- Understanding these variants is crucial for developing effective therapeutic strategies and improving patient outcomes.
- Further research into preS/S variant-associated liver disease is warranted.
Related Concept Videos
01:25Hepatitis
86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
01:28Viral Hepatitis I: Introduction
25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:05Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121